February 2, 2021
Ono Pharmaceutical enjoyed solid earnings in April-December as its PD-1 inhibitor Opdivo (nivolumab) racked up double-digit growth, while SGA outlays dwindled, a plus on the profit front, due to subdued sales activities rendered by the COVID-19 crisis. In the first...read more